Literature DB >> 9195508

Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study.

A E Clarke1, H Zowall, C Levinton, H Assimakopoulos, J T Sibley, M Haga, J Shiroky, C Neville, D P Lubeck, S A Grover, J M Esdaile.   

Abstract

OBJECTIVE: To perform the first prospective longitudinal study of direct (health services utilized) and indirect costs (diminished productivity represented by income loss) incurred by patients with rheumatoid arthritis (RA) in Saskatoon and Montreal, followed for up to 12 and 4 years, respectively.
METHODS: 1063 patients reported on health status, health services utilization, and diminished productivity every 6 months.
RESULTS: Annual direct costs were $3788 (1994 Canadian dollars) in the late 1980s and $4656 in the early 1990s. Given that the average age exceeded 60 years, few participated in labor force activities or considered themselves disabled from the labor force and their indirect costs were substantially less, $2165 in the late 1980s and $1597 in the early 1990s. Institutional stays and medications made up at least 80% of total direct costs. Lengths of stay in acute care facilities remained constant, but the rate of hospitalization increased in the early 1990s, increasing average hospital costs per patient from $1563 in the late 1980s to $2023 in the early 1990s. For nonacute care facilities, rate of admission as well as length of stay increased over time, increasing costs per patient in Saskatoon 5-fold, from $291 to $1605. Those with greater functional disability incurred substantially higher direct and those under 65 years incurred higher indirect costs.
CONCLUSION: Direct costs are higher than indirect costs. The major component is due to institutional stays that, in contrast to other direct cost components, is increased in the older and more disabled. Measures to reduce longterm disability by earlier, more aggressive intervention have the potential to produce considerable cost savings. However, it is unknown which strategies will have the greatest effect on outcome and accordingly, how resources can be optimally allocated.

Entities:  

Mesh:

Year:  1997        PMID: 9195508

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  23 in total

Review 1.  Does hemopoietic stem cell transplantation have a role in treatment of severe rheumatoid arthritis?

Authors:  R M Lowenthal; S R Graham
Journal:  J Clin Immunol       Date:  2000-01       Impact factor: 8.317

2.  The case for stratified cost-effectiveness analysis by baseline health-related QOL: theory and sensitivity analysis.

Authors:  Joseph Schaafsma
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.

Authors:  Hubertus Rosery; Rito Bergemann; Stefanie Maxion-Bergemann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.

Authors:  Marco Barbieri; John B Wong; Michael Drummond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

6.  Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial.

Authors:  Andreas Maetzel; Vibeke Strand; Peter Tugwell; George Wells; Claire Bombardier
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  The impact of rheumatoid arthritis and biologics on employers and payers.

Authors:  Paresh Chaudhari
Journal:  Biotechnol Healthc       Date:  2008-07

Review 8.  A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings.

Authors:  D P Lubeck
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 9.  Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States.

Authors:  Nick Bansback; Roberta Ara; Jonathan Karnon; Aslam Anis
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

10.  Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany.

Authors:  D Huscher; S Merkesdal; K Thiele; H Zeidler; M Schneider; A Zink
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.